The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index; 9 of the 22 sources its claims cite were checked for support.
Albendazole-induced granulomatous hepatitis: a case report
Open accessAbstract
Case report of albendazole-induced granulomatous hepatitis diagnosed after exclusion of other causes and improvement after withdrawal.
Overview
CoChat Summary
TL;DR
This case report describes a 25-year-old Hispanic woman with acute hepatitis of unknown etiology who was diagnosed with albendazole-induced granulomatous hepatitis after other causes were excluded and her liver profile improved after drug withdrawal. The CIOMS-RUCAM score was 5 (“possible”), and liver biopsy showed non-necrotizing epithelioid granulomas.
Key findings
- A 25-year-old Hispanic woman presented with progressive jaundice, right upper quadrant pain, fatigue, weakness, and dark urine, without acholia, fever, or vomiting; liver and biliary ultrasonography were normal.
- Liver biopsy showed portal inflammatory infiltrate of lymphocytes, plasma cells, and neutrophils, hepatocyte necrosis of the limiting plate, and macrophage infiltrate with non-necrotizing epithelioid granulomas in the hepatic sinusoids; special stains for tuberculosis and fungi were negative, and chest/abdomen CT was normal.
- Detailed drug history revealed albendazole, paracetamol, and hyoscine butyl bromide 2 weeks before jaundice; after medication withdrawal, the patient had gradual normalization of liver biochemical profile without specific treatment, with follow-up at 2 and 6 months showing spontaneous resolution.
- The CIOMS-RUCAM scale showed a “possible” relationship with a score of 5; the paper also notes that in clinical trials albendazole was associated with mild to moderate liver enzyme elevations in about 16% of patients, and up to 17% of acute liver failure cases are attributed to idiosyncratic reactions.
Methods
- Single case report of one 25-year-old Hispanic woman admitted to a Clinical Hepatology Unit with symptoms of acute hepatitis of unknown etiology.
- Diagnostic workup included laboratory studies, liver and biliary ultrasonography, percutaneous ultrasound-guided liver biopsy, special stains for tuberculosis and fungi, contrasted CT of the chest and abdomen, stool specimen, detailed drug history, and CIOMS-RUCAM causality assessment.
- Main analysis was descriptive: exclusion of other possible causes, histologic pattern, drug history, and spontaneous improvement after medication withdrawal.
Limitations
- The paper states that diagnosis of drug-induced liver injury is one of exclusion, with no absolute criteria or specific method, heterogeneous clinical presentation and evolution, poorly understood risk factors and pathogenesis, and no models for predicting adverse reactions.
- The paper reports a CIOMS-RUCAM score of 5 (“possible”), not a higher category, and notes that only three articles were indexed in MEDLINE at the time of review.
- Evident from the text: this is a single-patient case report without a control or rechallenge, so it cannot establish incidence or causality beyond this patient.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
6 Valid · 1 Not valid · 5 Not checked · 16 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A subsequent review of all autoimmune markers indicated that these were negative.”
§ Albendazole-induced granulomatous hepatitis: a case report > Discussion
hedgedSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Special stains for tuberculosis and fungi were negative.”
§ Albendazole-induced granulomatous hepatitis: a case report > Case presentation
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the time of this review, only three articles were indexed in MEDLINE”
§ Albendazole-induced granulomatous hepatitis: a case report > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A more detailed questioning revealed that 2 weeks before the jaundice, the patient had received empirical treatment with albendazole and paracetamol and hyoscine butyl bromide for nonspecific gastrointestinal symptoms.”
§ Albendazole-induced granulomatous hepatitis: a case report > Case presentation
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CIOMS-RUCAM scale showed a “possible” relationship with a score of five points, which supported the diagnosis of albendazole-induced granulomatous hepatitis with a pattern of hepatocellular DILI damage.”
- Also stated in: § Conclusions · plain
“The CIOMS-RUCAM scale showed a “possible” relationship with a score of five, which supported the diagnosis of albendazole-induced granulomatous hepatitis with a pattern of hepatocellular damage.”
§ Albendazole-induced granulomatous hepatitis: a case report > Discussion
plainstates a possible causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Conclusions · plain
3 more claims
Create a free account to see all 28 claims and every source verdict.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, however, even a single dose treatment (for empirical or seasonal use) of albendazole (400 mg) could cause acute liver toxicity in adult patients [39,314–318] as well as in children [319–322].”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [316]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Albendazole-induced granulomatous hepatitis: a case report > Abstract > Case presentation
“This diagnosis was supported by the Council for International Organizations of Medical Sciences-Roussel Uclaf Causality Assessment Method, which showed a likely correlation between hepatocellular damage and drug toxicity as the etiology.”
§ Albendazole-induced granulomatous hepatitis: a case report > Conclusions
“The CIOMS-RUCAM scale showed a “possible” relationship with a score of five, which supported the diagnosis of albendazole-induced granulomatous hepatitis with a pattern of hepatocellular damage.”
Citations
Cites
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Criteria of drug-induced liver disorders
(1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90124-a · Cited by 1,106 · cited 4×
“These findings are consistent with those found in other studies where antibiotics, nonsteroidal antiinflammatory drugs, and immunomodulatory drugs have been implicated as a cause of drug-induced hepatotoxicity [6,8-10].”
BackgroundMethodResultInfluentialAndrade, R. J., Lucena, I. M., Kaplowitz, N., García-Muņoz, B., Borraz, Y., Pachkoria, K., García-Cortés, M., Fernández, C. M., Pelaez, G., Rodrigo, L., et al. (2006) · Hepatology · doi:10.1002/hep.21424 · Cited by 309
Idiosyncratic drug-induced liver injury: an overview
Hussaini, S. H., & Farrington, E. A. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.6.673 · Cited by 183
Drug-induced liver injury: a clinical update
Ghabril, M., Chalasani, N., & Björnsson, E. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283383c7c · Cited by 123 · cited 3×
“Hepatocellular injury patterns are more common in younger patients, whereas patterns of cholestasis prevail in older patients [3,5,7].”
BackgroundHepatology: A textbook of liver disease
(1983) · doi:10.1016/0016-5085(83)90470-5 · Cited by 75
Acute Drug-Induced Hepatitis Caused by Albendazole
Choi, G. Y., Yang, H. W., Cho, S. H., Kang, D. W., Go, H., Lee, W. C., Lee, Y. J., Jung, S. H., Kim, A. N., & Cha, S. W. (2008) · Journal of Korean Medical Science · doi:10.3346/jkms.2008.23.5.903 · Cited by 54
Antibiotic-Induced Liver Toxicity: Mechanisms, Clinical Features and Causality Assessment
Robles, M., Toscano, E., Cotta, J., Isabel Lucena, M., & J. Andrade, R. (2010) · Current Drug Safety · doi:10.2174/157488610791698307 · Cited by 45
Granulomatous Hepatitis Due to Mebendazole
Colle, I., Naegels, S., Hoorens, A., & Hautekeete, M. (1999) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199901000-00010 · Cited by 27
Toxicidad hepática recurrente secundaria a metilprednisolona intravenosa
Fernández, M. R., Riesco, J. M., Moreira, V. F., Moreno, A., Román, A. L. S., Arranz, G., & Arbol, L. R. D. (2008) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082008001100010 · Cited by 26
Research works printed but not linked: 1
- Fernandez MR, Riesco JM, Moreira VF, Moreno A, San Roman AL, Arranz G, Ruiz Del Arbol L: Recurrent hepatic toxicity secondary to intravenous methylprednisolone. Rev Esp Enferm Dig. 2008, 100 (11): 720-723.
Cited by
Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update
Chai, J.-Y., Jung, B.-K., & Hong, S.-J. (2021) · The Korean Journal of Parasitology · doi:10.3347/kjp.2021.59.3.189 · Cited by 286
Albendazole and Praziquantel: Review and Safety Monitoring in Korea
Hong, S.-T. (2018) · Infection & Chemotherapy · doi:10.3947/ic.2018.50.1.1 · Cited by 65
“However, more serious cases were reported following combined or prolonged medication, such as drug-induced psychosis by ADZ + IVM therapy [10], hemolytic anemia and kidney and brain injuries inducing acute renal failure by intravenous injection of ADZ [11], loss of body hair [12], and toxic hepatitis [13-15].”
BackgroundChhonker, Y. S., Edi, C. V. A., & Murry, D. J. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.12.037 · Cited by 38
Mironova, M., Gopalakrishna, H., Franco, G. R., Holland, S. M., Koh, C., Kleiner, D. E., & Heller, T. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000392 · Cited by 39
Metadata
- Authors
- Marin Zuluaga, J. I., Marin Castro, A. E., Perez Cadavid, J. C., & Restrepo Gutierrez, J. C.
- Venue
- Journal of Medical Case Reports
- Published
- 2013-07-26
- Volume
- 7
- Issue
- 1
- Pages
- 201-201
- ISSN
- 1752-1947 (ISSN-L)
- PMC
- PMC3750323
- OpenAlex
- W2154715170
- Cited by
- 45
- References
- 14
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 4 · 2021: 6 · 2020: 2 · 2019: 2 · 2018: 6 · 2017: 6 · 2015: 1 · 2014: 4 · 2013: 1
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0 (tdm)
- Locations
- Journal of Medical Case Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repository University of Antioquia (University of Antioquia) (submittedVersion, cc-by-nc)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- albendazole, drug-induced liver injury, granulomatous hepatitis, hepatotoxicity, liver biopsy, drug withdrawal, RUCAM, acute hepatitis, antiparasitic drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Albendazole-induced granulomatous hepatitis: a case report. https://app.cochat.ai/papers/10.1186/1752-1947-7-201
- The paper
- Marin Zuluaga, J. I., Marin Castro, A. E., Perez Cadavid, J. C., & Restrepo Gutierrez, J. C. (2013). Albendazole-induced granulomatous hepatitis: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/1752-1947-7-201
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.